Access to regulatory data from the European Medicines Agency: The times they are a-changing

Systematic Reviews

Volumn 1, Issue 1, 2012, Pages

  Wieseler, Beate ^a   McGauran, Natalie ^a   Kerekes, Michaela F ^a   Kaiser, Thomas ^a  

^a INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE IQWIG   (Germany)

Author keywords

Clinical study reports; European Medicines Agency; Individual patient data listings; Publication bias; Raw data; Regulatory authorities; Systematic reviews

Indexed keywords

OSELTAMIVIR; PLACEBO; REBOXETINE; DRUG;

ARTICLE; CLINICAL RESEARCH; HEALTH CARE; HEALTH CARE POLICY; HEALTH SERVICE; HUMAN; LAW; SYSTEMATIC REVIEW; CLINICAL TRIAL (TOPIC); CONFIDENTIALITY; CONFLICT OF INTEREST; DRUG APPROVAL; DRUG INDUSTRY; DRUG SCREENING; EDITORIAL; EUROPE; EVIDENCE BASED MEDICINE; LITERATURE; POSTMARKETING SURVEILLANCE; PUBLISHING; QUALITY CONTROL; RESEARCH; STANDARD;

CLINICAL TRIALS AS TOPIC; CONFIDENTIALITY; CONFLICT OF INTEREST; DRUG APPROVAL; DRUG EVALUATION; DRUG INDUSTRY; EUROPE; EVIDENCE-BASED MEDICINE; HEALTH POLICY; HUMANS; PHARMACEUTICAL PREPARATIONS; PRODUCT SURVEILLANCE, POSTMARKETING; PUBLICATION BIAS; QUALITY CONTROL; RESEARCH REPORT; REVIEW LITERATURE AS TOPIC;

EID: 84870562248     PISSN: None     EISSN: 20464053     Source Type: Journal    
DOI: 10.1186/2046-4053-1-50     Document Type: Article

References (22)

1. Song F, Parekh S, Hooper L, Loke YK, Ryder J, Sutton AJ, Hing C, Kwok CS, Pang C, Harvey I. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess 2010, 14(8):1-220.
2. McGauran N, Wieseler B, Kreis J, Schüler YB, Kölsch H, Kaiser T. Reporting bias in medical research: a narrative review. Trials 2010, 11(1):37. 10.1186/1745-6215-11-37, 2867979, 20388211.
3. Wieseler B, Kerekes MF, Vervoelgyi V, McGauran N, Kaiser T. Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications. BMJ 2012, 344:d8141. 10.1136/bmj.d8141, 22214759.
4. Gotzsche PC, Jorgensen AW. Opening up data at the European Medicines Agency. BMJ 2011, 342:d2686. 10.1136/bmj.d2686, 21558364.
5. Eyding D, Lelgemann M, Grouven U, Harter M, Kromp M, Kaiser T, Kerekes MF, Gerken M, Wieseler B. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 2010, 341:c4737. 10.1136/bmj.c4737, 2954275, 20940209.
6. Doshi P, Jefferson T, Del Mar C. The imperative to share clinical study reports: recommendations from the Tamiflu experience. PLoS Med 2012, 9:e1001201. 10.1371/journal.pmed.1001201, 3323511, 22505850.
7. Bupropion, mirtazapine and reboxetine in the treatment of depression Final report; commission no A05-20C in German http://www.iqwig.de/download/A05-20C_Abschlussbericht_Bupropion_Mirtazapin_und_Reboxetin_bei_Depressionen.pdf, Bupropion, mirtazapine and reboxetine in the treatment of depression.
8. Doshi P. Neuraminidase inhibitors: the story behind the Cochrane review. BMJ 2009, 339:b5164. 10.1136/bmj.b5164, 19995813.
9. European Medicines Agency widens public access to documents Policy on access to documents also sets out new approach for proactive disclosure of documents www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/11/news_detail_001158.jsp&mid=WC0b01ac058004d5c1&murl=menus/news_and_events/news_and_events.jsp, European Medicines Agency widens public access to documents.
10. Eichler HG, Abadie E, Breckenridge A, Leufkens H, Rasi H. Open clinical trial data for all? A view from regulators. PLoS Med 2012, 9(4):e1001202. 10.1371/journal.pmed.1001202, 3323505, 22505851.
11. mo M. Principles to be applied for the implementation of the HMA/EMA guidance on the identification of CCI and PPD in MA applications http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/03/WC500124537.pdf.
12. me M. HMA/EMA guidance document on the identification of commercially confidential information and personal data within the structure of the Marketing Authorisation (MA) application - release of information after the granting of a Marketing Authorisation http://www.hma.eu/fileadmin/dateien/HMA_joint/02-_HMA_Topics/07-Transparency/2012_03_HMA_EMA_Guidance_20120309_ComPersInfo.pdf.
13. meow M. Guideline for industry: structure and content of clinical study reports http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm129456.pdf.
14. Kirwan JR. Making original data from clinical studies available for alternative analysis. J Rheumatol 1997, 24(5):822-825.
15. Hutchon DJ. Publishing raw data and real time statistical analysis on e-journals. BMJ 2001, 322(7285):530. 10.1136/bmj.322.7285.530, 1119735, 11230070.
16. Vickers AJ. Whose data set is it anyway? Sharing raw data from randomized trials. Trials 2006, 7:15. 10.1186/1745-6215-7-15, 1489946, 16704733.
17. Hrynaszkiewicz I, Norton ML, Vickers AJ, Altman DG. Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers. Trials 2010, 11:9. 10.1186/1745-6215-11-9, 2825513, 20113465.
18. wof M. Cochrane handbook for systematic reviews of interventions, Version 5.1.0 http://www.cochrane-handbook.org.
19. arf M. General methods: version 4.0 https://www.iqwig.de/download/General_Methods_4-0.pdf.
20. Lenzer J. FDA is incapable of protecting US "against another Vioxx". BMJ 2004, 329(7477):1253. 10.1136/bmj.329.7477.1253, 534432, 15564236.
21. Moore TJ. Deadly medicine: why tens of thousands of heart patients died in America's worst drug disaster 1995, Simon & Schuster, New York.
22. dimension M. Workshop on access to clinical trial data and transparency http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/events/2012/07/event_detail_000656.jsp&mid=WC0b01ac058004d5c3.